Premium
Establishment and characterization of a MALT lymphoma cell line carrying an API2‐MALT1 translocation
Author(s) -
Izumi Kiyotaka,
Nishikori Momoko,
Yuan Hepei,
Otsuka Yasuyuki,
Nakao Kensuke,
TakaoriKondo Akifumi
Publication year - 2020
Publication title -
genes, chromosomes and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.754
H-Index - 119
eISSN - 1098-2264
pISSN - 1045-2257
DOI - 10.1002/gcc.22855
Subject(s) - chromosomal translocation , lymphoma , malt lymphoma , bcl10 , biology , cancer research , mantle cell lymphoma , cell culture , gene , genetics , immunology
MALT lymphomas with API2(BIRC3)‐MALT1 translocation usually have an indolent clinical course and rarely transform into aggressive lymphoma, and there have been no lymphoma cell lines carrying API2‐MALT1 translocation reported to date. We established a novel lymphoma cell line named BMA19, carrying the API2‐MALT1 translocation from a patient with histologic transformation of intestinal MALT lymphoma. The cells were suggested to carry API2‐MALT1 and MYC‐IGH translocations by chromosomal analysis, and these translocations were confirmed by polymerase chain reaction analysis. The expression of MYC was shown to be enhanced as a result of the MYC‐IGH translocation, and it is considered to have played a role in the histologic transformation of MALT lymphoma. Whole exome sequencing of BMA19 identified several nucleotide variations in genes reported to be mutated in previous studies of marginal zone lymphomas. The MALT1 inhibitor MI‐2 specifically decreased cell growth, and the BMA19 cell line was suggested to be still dependent on the API2‐MALT1 signal. Subtractive microarray analysis showed that one of the earliest events resulting from MALT1 inhibition is increased susceptibility to endoplasmic reticulum stress‐induced apoptosis. The BMA19 cell line is considered to conserve the biological properties of MALT lymphoma and is expected to be a valuable tool for research into the pathogenesis of MALT lymphoma with an API2‐MALT1 translocation.